LINCOLN, Neb.–(BUSINESS WIRE)–The Arbor Day Foundation is using a new data-driven metric to better understand how many people are impacted by the trees it plants and distributes in communities. Known as the “People Impacted Metric,” the data layer gives the Foundation a clearer picture of how many people stand to benefit from a given tree planting or distribution project. “Clearly communicating the benefit of a tree planting project helps people understand the difference their support makes o

LEAWOOD, Kan.–(BUSINESS WIRE)—- $AMC–AMC Entertainment Holdings, Inc. (NYSE: AMC) (the “Company,” or “AMC”), announced today that it has commenced an offering of $2,000 million aggregate principal amount of first lien notes due 2031 (the “Notes”) in a private offering (the “Offering”) and launched syndication of a new $850 million first lien term loan facility (the “New 1L Term Loan Facility” and together with the Offering, the “1L Financing”), each subject to market and other conditions. The Compan

U.S. rare earth permanent magnet producer becomes a constituent of both indexes effective at the opening of U.S. equity markets on September 21, 2026, following finalization of FTSE Russell’s third-quarter 2026 quarterly IPO additions

MIAMI, FL, Sept. 21, 2026 (GLOBE NEWSWIRE) — Evolution Metals & Technologies Corp. (“EM&T” or the “Company”) (Nasdaq: EMAT), a U.S.-based critical materials and advanced manufacturing company producing rare earth permanent magnets, battery materials and related critical minerals, today announced that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective as of the opening of U.S. equity markets today, Monday, September 21, 2026. The addition was finalized through FTSE Russell’s third-quarter 2026 quarterly IPO additions process, placing EM&T in two of the most widely tracked U.S. equity benchmarks in its first year as a Nasdaq-listed company.

Membership in the Russell 2000® Index results in automatic inclusion in the broad-market Russell 3000® Index and in the applicable Russell U.S. style indexes. According to FTSE Russell, approximately $12.2 trillion in assets are benchmarked to or invested in products based on the Russell U.S. Indexes, which institutional investors use for index funds and as benchmarks for both active and passive strategies. As an official constituent, EM&T is now being incorporated into index-tracking investment products and institutional portfolios, and is immediately eligible for active managers whose mandates require benchmark membership.

“Joining the Russell 2000 and Russell 3000 indexes is a defining capital-markets milestone for EM&T and a direct reflection of the operational and commercial execution we have delivered since our Nasdaq listing earlier this year,” said Christopher Clower, Chief Financial Officer and Chief Operating Officer of EM&T. “In eight months we have moved EM&T into commercial-scale production. We have validated our non-China supply chain, secured ex-China NdPr feedstock, advanced our Pohang infrastructure expansion to scale annual magnet production to 10,000 metric tons, and established initial revenue guidance of $400 million to $460 million for fiscal 2027. Constituent status in two of the most widely followed U.S. equity benchmarks puts EM&T directly in front of the institutional capital that indexes to them, and it comes as the market moves to meet the critical defense sourcing requirements taking effect under DFARS on January 1, 2027.”

The index additions coincide with the ongoing commercial expansion of EM&T’s rare earth permanent magnet platform in Pohang, Republic of Korea. Supported by a 750-megawatt electrical infrastructure agreement with KEPCO and thirteen additional ULVAC sintered magnet production machines scheduled for delivery in November 2026, the Company is ramping annual production capacity to approximately 10,000 metric tons, including 6,000 metric tons of high-performance sintered NdFeB magnets, utilizing secured non-China NdPr feedstock.

For more information on the Russell U.S. Indexes and the quarterly IPO additions process, visit https://www.lseg.com/en/ftse-russell/russell-reconstitution/ipo-additions.

Russell®, Russell 2000® and Russell 3000® are trademarks of Frank Russell Company, used under license by FTSE Russell, an LSEG business. FTSE Russell does not sponsor, endorse, sell or promote Evolution Metals & Technologies Corp. or its securities, and makes no representation regarding the advisability of investing in the Company.

About Evolution Metals & Technologies Corp.
Evolution Metals & Technologies Corp. (Nasdaq: EMAT) is a U.S.-based critical materials and advanced manufacturing company for rare earth permanent magnets, battery materials, and related critical minerals and technologies. By leveraging proven commercial-scale operations, advanced processing technologies, and strategic partnerships, EM&T operates what it believes is the only vertically integrated critical materials supply chain spanning end-of-life electronics and batteries, high-grade concentrates, and the manufacture of finished rare earth magnets (including high-performance rare earth magnets) and battery materials. For additional information, please visit https://investors.evolution-metals.com and follow the Company on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding EM&T’s inclusion in the Russell 3000® and Russell 2000® Indexes and applicable style indexes, the timing and potential effects of such inclusion, including potential visibility among institutional or index-oriented investors, trading liquidity, shareholder base diversification, and index-tracking fund representation; EM&T’s plans, objectives, expectations, strategies, production capacity, expansion initiatives, supply arrangements and commercial operations; the installation, commissioning and delivery schedule of thirteen additional ULVAC production machines; the planned expansion of electrical infrastructure to 750 megawatts in Pohang; and initial revenue guidance for fiscal years 2026 and 2027. These forward-looking statements, together with terms such as anticipate, expect, intend, may, will, should, believe, positioned and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such risks include, among others, the possibility that index inclusion may not result in the anticipated visibility, liquidity, institutional ownership, index fund representation or other benefits; that FTSE Russell may revise its index methodology, constituent determinations, or implementation schedules in future periods; and the business, execution, financing, regulatory, supply-chain, power infrastructure, equipment-delivery, customer-qualification and market risks described in EM&T’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results, performance or achievements may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date made. EM&T undertakes no obligation to update any forward-looking statement except as required by law. Additional information concerning factors that may affect EM&T’s expectations and projections is contained in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, filed with the SEC on August 17, 2026, including the disclosures under “Risk Factors” therein, and other documents filed or to be filed with the SEC by EM&T. SEC filings are available at www.sec.gov.

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
www.arxhq.com
EMAT@arxhq.com

PR, Media & Global Communications Contact:
Phoenix MGMT & Consulting
www.PhoenixMGMTConsulting.com
PR@PhoenixMGMTConsulting.com
888-228-0122

LOS ANGELES–(BUSINESS WIRE)—- $NAGE #Biotech–Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offspring

ATHENS, Greece, Sept. 21, 2026 (GLOBE NEWSWIRE) — Rubico Inc. (Nasdaq: RUBI) (the “Company” or “Rubico”), a global provider of shipping transportation services specializing in the ownership of vessels, announced today that it will transition from semi-annual to quarterly reporting of its financial results, beginning with the announcement of its results for the third quarter and nine months ended September 30, 2026, which the Company expects to release during the fourth quarter of 2026.

Each quarterly earnings release will include unaudited condensed financial statements, comprising a statement of operations for the relevant quarterly and year-to-date periods, a balance sheet as of the end of the relevant period and a summarized statement of cash flows for the relevant quarterly and year-to-date periods, together with selected operating data and operational updates. The quarterly earnings releases will not include accompanying notes to the financial statements. As a foreign private issuer, the Company will continue to furnish to the U.S. Securities and Exchange Commission unaudited interim condensed consolidated financial statements with accompanying notes on a semi-annual basis, and to file audited annual consolidated financial statements with its annual report on Form 20-F.

The transition to quarterly earnings reporting reflects the Company’s commitment to enhanced transparency and more frequent communication with the investment community, and aligns the frequency of the Company’s reporting with that of many of its listed peers.

About the Company

Rubico Inc. is a global provider of shipping transportation services specializing in the ownership of vessels. The Company is an international owner and operator of two modern, fuel efficient, eco 157,000 dwt Suezmax tankers. Furthermore, the Company owns two 47,499 dwt MR tanker newbuildings scheduled for delivery in the third and fourth quarters of 2029 and a 60-meter newbuilding megayacht scheduled for delivery in the second quarter of 2027, which the Company intends to divest. In addition, the Company has entered into a share purchase agreement to acquire a shipowning company that owns one high-specification 47,499 dwt MR tanker newbuilding scheduled for delivery in the second quarter of 2029, with closing of this share purchase agreement to occur by September 30, 2026.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “RUBI”.

Please visit the Company’s website at: https://rubicoinc.com/

For further information please contact:

Nikolaos Papastratis
Chief Financial Officer
Rubico Inc.
Tel: +30 210 812 8107
Email: npapastratis@rubicoinc.com

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the timing, frequency and content of the Company’s future financial reporting and earnings releases.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

Exascale Labs CEO Hoansoo Lee, Nobel Laureate David Card, Berkeley economist Shachar Kariv, Samsung Ventures’ Jaeyoung Shin comprise the post-closing board of directors, led by Founding Investor Wenying Jia

SAN FRANCISCO, Sept. 21, 2026 (GLOBE NEWSWIRE) — Following the completion of its business combination, Exascale Labs Inc. (“Exascale” or the “Company”) (Nasdaq: XLAB), a provider of next-generation AI compute infrastructure, today announced the composition of its Board of Directors.

“We are pleased to have completed our business combination and are confident in our strategy, balance sheet, and leadership team as we move forward as a publicly traded company,” said Hoansoo Lee, Chief Executive Officer of Exascale Labs. “Wenying, who chairs our Board, has been with us since inception, and she understands GPU infrastructure at a level very few investors do. We are especially honored to have David Card, a Nobel Laureate in Economic Sciences, on our Board. His empirical rigor and standing in the economics profession bring a level of analytical credibility that is rare in the AI infrastructure sector, and together with Shachar’s and Jaeyoung’s expertise, gives us a Board built for the discipline required to scale a capital-intensive compute platform in public markets.”

Board of Directors
Following the closing of the Business Combination, the Board consists of Dr. Card, Dr. Kariv, Mr. Shin, Dr. Lee and Ms. Jia. Ms. Jia serves as Chair, and Dr. Card serves as Lead Independent Director.

David Card. Dr. Card is a labor economist and Nobel Laureate, and is the Class of 1950 Emeritus Professor of Economics at the University of California, Berkeley, where he has been a member of the faculty since 1997. Prior to joining Berkeley, Dr. Card held academic appointments at Princeton University and the University of Chicago. He was awarded the 2021 Nobel Memorial Prize in Economic Sciences for his empirical contributions to labor economics, and is widely recognized for his work on labor markets, education, immigration and wage dynamics. Dr. Card previously served as President of the American Economic Association and has held editorial roles at several leading academic journals. He is a Fellow of the American Academy of Arts and Sciences and the Econometric Society. Dr. Card received his B.A. from Queen’s University and his M.A. and Ph.D. in Economics from Princeton University.

Shachar Kariv. Dr. Kariv is an economist and the Benjamin N. Ward Professor of Economics at the University of California, Berkeley, a position he has held since 2014, having joined the Department of Economics faculty in 2003 and twice served as Department Chair. Dr. Kariv’s research focuses on economic theory, experimental economics and behavioral economics, and he has held visiting positions at the Institute for Advanced Studies, the European University Institute, Stanford University, the University of Cambridge and the Norwegian School of Economics. He has received numerous teaching awards, including the Earl F. Cheit Award for Excellence in Teaching from the Haas School of Business. Dr. Kariv earned his B.A. in Economics from Tel Aviv University and his M.A. and Ph.D. in Economics from New York University.

“My research is in decision theory, game theory, and experimental economics, focused on how people and organizations make decisions under uncertainty,” said Dr. Shachar Kariv, Benjamin N. Ward Professor of Economics, UC Berkeley. “AI infrastructure is a natural extension of that work, and the questions Exascale faces about capacity, pricing, investment timing, and how to allocate scarce compute are economic questions at their core. I’m looking forward to working on them from the board. From my experience, a board is most useful when it asks the right questions and challenges management’s assumptions, not when it applies theory mechanically. That’s what I hope to bring to Exascale.”

Jaeyoung Shin. Mr. Shin is Vice President and Head of Asia at Samsung Ventures Investment Corporation, where he oversees the firm’s investment activities across Greater China, Japan, India and Southeast Asia. Since joining Samsung Ventures in 2010, Mr. Shin has led and supported investments across semiconductors, AI chips, image sensors, display technologies and other advanced technology sectors, with notable IPO and M&A exits including Montage Technology, VeriSilicon, Silergy, Amlogic, GalaxyCore, SmartSens, Deep Glint, DeePhi and PlayNitride. Prior to Samsung Ventures, Mr. Shin worked as a fuel cell researcher at the Samsung Advanced Institute of Technology in Korea and at the Fuel Cell Lab of Forschungszentrum Jülich in Germany. Mr. Shin holds a Bachelor’s degree in Mechanical Engineering from Aachen University of Applied Science in Germany.

Hoansoo Lee. Dr. Lee is a co-founder of Exascale and has served as Exascale’s Chief Executive Officer and a member of its board of directors since June 2022, roles he continues to hold following the completion of the Business Combination. Previously, from 2020 to 2025, Dr. Lee was the founder and Chief Executive Officer of HSL Capital Management LLC, a multi-strategy hedge fund. Earlier in his career, he served as a Staff Economist for the Council of Economic Advisers, Assistant Professor of Finance at Tsinghua University, and Managing Director for TusPark Ventures, where he led cross-border early-stage technology investments. Dr. Lee earned a B.A. in Mathematics and Economics from the University of California, Berkeley, and an A.M. and Ph.D. in Business Economics from Harvard University.

Wenying Jia, Chair. Ms. Jia has served as a member of the board of directors of Exascale since inception and was among one of the company’s earliest investors. Ms. Jia is an angel investor with experience in digital assets, cloud computing and emerging technology infrastructure, and has been involved in the digital asset sector since 2014, and expanded into GPU-based mining operations in 2017 as Ethereum’s proof-of-work network gained adoption. From 2017 through 2022, she invested in and supported multiple GPU- and data-storage-related infrastructure projects, and during this period developed relationships with several individuals who later became core members of Exascale. Ms. Jia played a significant role in facilitating the formal establishment of Exascale in 2022. As a founding-era director, Ms. Jia brings early-stage investor experience, long-standing expertise in GPU-based infrastructure and institutional knowledge of the Company and its core team.

About Exascale Labs
Exascale is a next-generation AI infrastructure provider operating a software-defined GPU compute platform and related AI infrastructure solutions. Its business includes Token Factory, GPU-as-a-service, GPU cluster management and optimization, and infrastructure solutions spanning modular data centers, HVDC power, high-density cooling, and data center interconnectivity. Exascale’s platform supports large-scale AI workloads, including training, fine-tuning, high-concurrency inference, and API-based token generation. For more information, visit www.exascalelabs.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “can,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “will,” and similar expressions. These statements include, without limitation, statements regarding Exascale’s future financial and operating performance, its business strategy and growth plans, anticipated demand for AI infrastructure and compute capacity, planned deployment of modular data center, liquid cooling, HVDC power and energy storage solutions, expectations regarding additional financing, and Exascale’s competitive and market positioning.

These statements are based on current expectations and assumptions, and involve risks and uncertainties that could cause actual results or events to differ materially, including, among others, changes in customer demand, supply constraints for GPUs and related infrastructure components, Exascale’s ability to convert its sales pipeline into revenue, competitive pressures from larger and better-capitalized providers, technological risks, operational and execution risks associated with scaling infrastructure deployments, Exascale’s ability to access financing on favorable terms, regulatory changes, and macroeconomic factors.

If any of these risks materialize or the assumptions prove incorrect, actual results could differ materially from the results contained in or implied by these forward-looking statements. There may be additional risks that Exascale presently does not know of or cannot anticipate, or that Exascale currently believes are immaterial, that could also cause actual results to differ materially from those contained in or implied by the forward-looking statements.

Forward-looking statements reflect Exascale’s expectations, plans or forecasts of future events and views as of the date of this press release. Exascale anticipates that subsequent events and developments will cause its assessments to change. However, while Exascale may elect to update these forward-looking statements at some point in the future, Exascale specifically disclaims any obligation to do so.

Readers are referred to Exascale’s most recent SEC filings. Readers are cautioned not to place undue reliance upon any forward-looking statement.

Investor Contact
Nick Hresko-Staab
KCSA Strategic Communications
Exascale@KCSA.com

Media Contact
Hannah Erger
KCSA Strategic Communications
Exascale@KCSA.com

First acquisition since its IPO: Ticketplus converts its white-label partner in Argentina into its own operation, with Autoentrada founder Eric López leading the local business

SANTIAGO, Chile and CÓRDOBA, Argentina, Sept. 21, 2026 (GLOBE NEWSWIRE) — Ticketplus Ltd. (“Ticketplus” or the “Company”) (NYSE American: TP), a technology company that operates a proprietary, full-stack platform for the live-entertainment industry in Latin America, today announced that it has acquired Autoentrada S.A. (“Autoentrada”), an Argentine ticketing company based in Córdoba with more than two decades of operating history. This is Ticketplus’s first acquisition since its August 2026 initial public offering and expands the Company’s own brand into Argentina.

Ticketplus has a presence in 11 countries, with full operations in Chile, its home market, and now Argentina, and white-label partners across the other nine. Autoentrada has operated on Ticketplus’s platform under the white-label model since 2019, and the acquisition converts that relationship into full operations, complete with direct relationships with promoters and greater control over sales, payments, access and analytics. Autoentrada’s operating metrics are already included in Ticketplus’s platform metrics, but under full operations Ticketplus should capture a greater share of the value of each ticket. Operations will initially continue under the Autoentrada brand with the intention to progressively adopt the Ticketplus brand. The local team and promoter relationships are expected to continue under the leadership of Eric López.

More than two decades in the Argentine market

With roots dating to 1999 and a commercial brand launched in 2005, Autoentrada operates in 18 Argentine provinces across concerts, festivals, sports, theater, exhibitions and corporate events. Since 2005, it has managed more than 55,000 events and issued more than 18 million tickets.

Its credentials include ticketing home matches of the Argentine national team during the qualifiers for the FIFA World Cup Qatar 2022™, among them the last home match played before the World Cup at La Bombonera, the storied home stadium of Boca Juniors in Buenos Aires, in addition to ticketing Copa Argentina and the Cosquín National Folklore Festival.

Eric López joins Ticketplus as Country Manager for Argentina

Eric López, founder and president of Autoentrada, joins Ticketplus as Country Manager for Argentina, and will continue to lead the local team. His market knowledge and relationships with promoters and organizers will support commercial continuity during the integration.

“This acquisition is consistent with the strategy we outlined at our IPO: converting proven white-label partners into full operations. Because Autoentrada already operates on our platform, we are starting from a familiar operating base. With Eric leading the business, we are able to retain the team’s knowledge and expect to strengthen our direct relationships with promoters and ticket buyers.”

– Chien-Fu Chen, CEO of Ticketplus

“I know Ticketplus’s platform from using it for years at Autoentrada. Joining Ticketplus gives us regional scale and additional capabilities in payments, access and analytics while still maintaining the team and relationships we built in Argentina. With this, we believe the business can grow to a level we would not have reached on our own. I am joining with a long-term commitment, and I look forward to continuing to lead the local business in this new chapter.”

– Eric López, Founder of Autoentrada and Country Manager of Ticketplus Argentina

The Company, directly and indirectly through its subsidiary, Ticketplus SpA, acquired all issued and outstanding shares of Autoentrada. The financial terms of the transaction were not disclosed. Ticketplus does not expect the acquisition to have a material impact on its consolidated financial results for fiscal year 2026.

About Ticketplus

Ticketplus Ltd. (NYSE American: TP) is a technology company that operates a proprietary, full-stack platform for the live-entertainment industry in Latin America, integrating ticketing, payments, access control and analytics. The Company operates through a full-operations model and a white-label SaaS model across 11 countries: Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Paraguay, Peru, the United States, and Uruguay. In 2025, the Ticketplus platform processed more than 10.2 million tickets across more than 39,800 events, with Total Platform Sales (GMV) of approximately US$269 million. For more information, please visit the Ticketplus investor relations website at investors.ticketplus.com.

About Autoentrada

Autoentrada is an Argentine ticketing company with roots dating to 1999 and a commercial brand launched in 2005. Based in Córdoba, it operates across concerts, festivals, sports, theater, exhibitions, conferences and corporate events.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements about the expected benefits of the acquisition, regional presence, possible or assumed future results of operations, business strategies, potential growth opportunities, acquisitions or conversions, and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These forward-looking statements are not guarantees of future performance and are subject to risks that could cause material differences, including market conditions, developments in live entertainment, promoter and client relationships, competition, integration and other risks described in the Company’s SEC filings. Readers should not place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements except as may be required by law.

Contacts

Investor Relations: investors.ticketplus.com | Ticketplus@kcsa.com | Jack Perkins, KCSA

Dr. Elkeles Brings Deep Experience and Proven Track Record in Shaping Human Capital Strategy to Support Strategic Growth and Operational Execution

DELRAY BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Tamar Elkeles, PhD as a new independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.

Dr. Elkeles brings more than three decades of experience as an executive, board member, and strategic advisor across the technology, enterprise software and human capital industries. From 1992 to 2015, she served as Chief Learning & Talent Officer at Qualcomm, where she helped shape the human capital strategy that supported the company’s growth from $100 million to more than $25 billion in revenue and its global workforce from 700 to 35,000 employees. She currently serves as a Senior Advisor at East Wind Advisors, an Advisor at 444 Capital and a Venture Partner at Emerge Capital and she sits on the boards of Brightline Interactive and Open Sesame.

Dr. Elkeles’ appointment follows the Company’s recent announcement regarding its executive leadership transition, in which consumer and e-commerce sector veteran Jeff Willard was appointed Chief Executive Officer and President, succeeding Leslie C.G. Campbell, who served as Interim CEO and President alongside her role as Chair of the Board.

“As part of our ongoing commitment to proactive board refreshment and strong corporate governance, we are thrilled to welcome Tamar to the Board,” said Justin Mennen, incoming Chair of the Board. ” As PetMeds continues to scale and execute on its long-term growth priorities, Tamar’s deep experience and proven track record in building high-performing cultures and aligning talent with strategic growth will be an invaluable asset to our Board and leadership team,” added Mr. Mennen.

“I am honored to join the PetMeds Board of Directors at such a pivotal inflection point for the business,” said Dr. Elkeles. “With a solid operational and cultural foundation in place, I look forward to working with Justin, Jeff, and the entire Board to support PetMeds’ organizational growth priorities and drive long-term, sustainable value for our shareholders.”

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Forward-Looking Statements

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. These forward-looking statements include, without limitation, statements regarding the Company’s ability to deliver long-term sustainable value for its shareholders; and the Company’s ability to scale and, execute on its long-term growth priorities. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K filed on June 2, 2026 for the fiscal year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.